Abvc Biopharma (ABVC) Operating Leases (2019 - 2026)

Abvc Biopharma (ABVC) has reported Operating Leases for 8 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases rose 895.63% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (up 895.63% YoY), and the FY2025 full-year result was $1.6 million, up 575.97% from the prior year.
• Operating Leases climbed to $1.8 million in Q2 2026 per ABVC's latest filing, from $1.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $1.8 million in Q2 2026 and bottomed at $142201.0 in Q3 2024.
• Historically, Operating Leases has averaged $720146.3 across 5 years, with a median of $658581.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Leases tumbled 76.42% in 2025, then surged 895.63% in 2026.
• Over 5 years, Operating Leases stood at $791827.0 in 2022, then sank by 48.54% to $407457.0 in 2023, then sank by 41.88% to $236807.0 in 2024, then soared by 575.97% to $1.6 million in 2025, then grew by 10.17% to $1.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $1.8 million, $1.5 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.